China leads global trials for next-generation in vivo CAR-T therapies

China has emerged as a leader in clinical trials for innovative in vivo CAR-T-cell therapies, which engineer disease-fighting immune cells inside the patient's body to treat cancer, autoimmune diseases, and multiple sclerosis. Researchers note that China's large population, fast-track regulatory pathways, and resources drive this dominance, offering a cheaper and simpler alternative to ex vivo therapies.